ucleotide analog and/or peginterferon alpha-2a therapy for HBeAg-negative chronic hepatitis B.
- Conditions
- HBeAg-negative chronic hepatitis B
- Registration Number
- JPRN-UMIN000010594
- Lead Sponsor
- Gunma University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Not provided
1. patients receiving Shosaikoto. 2. patients with past history of interstitial pneumonitis. 3. patients with past history of hypersensitivity to peginterferon alpha-2a and other interferons. 4. patients with past history of hypersensitivity to biological products such as vaccine. 5. pregnant women, women who may be expecting a child or lactating woman. 6. patients with chronic renal failure or severe renal dysfunction with less than or equal to 50 mL/min Ccr. 7.patients with severe depression, suicidal thinking or suicide attempt or past history of any of these diseases. 8. patients with severe liver dysfunction. 9. patients with chronic hepatitis such as autoimmune hepatitis and alcoholic hepatitis. 10. patients judged as inappropriate by the attending physician. 11. patients with less than 1.9 LogIU/mL HBsAg and less than 2.9LogIU/mL HBcrAg.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method negative conversion of HBsAg
- Secondary Outcome Measures
Name Time Method